Showing results (191-200 of 211) with videos related to
Sort By:
Pageof 22
JAMA Oncology|October 15, 2020
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical TrialHidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2020
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 23, 2016
Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer studyKoichi Takayama, Shinji Atagi, Fumio Imamura, et al.Cancers|January 21, 2022
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 StudyTomoyasu Mimori, Takehito Shukuya, Ryo Ko, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study)Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary SiteHidetoshi Hayashi, Takayasu Kurata, Yuichi Takiguchi, et al.The Lancet. Healthy Longevity|September 13, 2022
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trialYoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, et al.Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in JapanSatoshi Watanabe, Hiroshige Yoshioka, Hiroshi Sakai, et al.Plos One|May 15, 2013
A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancerIssei Kurahashi, Yoshihiko Fujita, Tokuzo Arao, et al.Pageof 22